Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory C Ravizzini

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Polish Journal of Radiology|May 24, 2024
Assessing the effectiveness of MRI, <sup>18</sup>F-fluciclovine PET, SUV<sub>max</sub>, and PSA in detecting local recurrence of prostate cancer after prostatectomyMayur K Virarkar, Stephen K Gruschkus, Gregory C Ravizzini, et al.
American Journal of Nuclear Medicine and Molecular Imaging|June 3, 2021
Diagnostic performance of <sup>18</sup>F-fluciclovine PET/CT in prostate cancer patients with rising PSA level ≤ 0.5 ng/ml after multiple treatment failuresAjalaya Teyateeti, Achiraya Teyateeti, Gregory C Ravizzini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2010
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancerGustavo S P Meirelles, Heiko Schöder, Gregory C Ravizzini, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|October 27, 2019
Fully automated preparation of <sup>68</sup>Ga-PSMA-11 at curie level quantity using cyclotron-produced <sup>68</sup>Ga for clinical applicationsMai Lin, Vincenzo Paolillo, Robert T Ta, et al.
Prostate Cancer and Prostatic Diseases|December 13, 2017
The use of PET/CT in prostate cancerRoger Li, Gregory C Ravizzini, Michael A Gorin, et al.
The Journal of Urology|June 23, 2023
Diagnostic Performance and Safety of <sup>18</sup>F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). ReplyAshesh B Jani, Gregory C Ravizzini, Benjamin A Gartrell, et al.
Radiology|March 24, 2010
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlationBaris Turkbey, Peter A Pinto, Haresh Mani, et al.
The Journal of Urology|July 7, 2023
Reply by AuthorsAshesh B Jani, Gregory C Ravizzini, Benjamin A Gartrell, et al.
The Journal of Urology|May 1, 2023
Diagnostic Performance and Safety of <sup>18</sup>F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)Ashesh B Jani, Gregory C Ravizzini, Benjamin A Gartrell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 13, 2024
Interreader and Intrareader Reproducibility of <sup>18</sup>F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter StudiesPhillip H Kuo, Giuseppe Esposito, Gary A Ulaner, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Polish Journal of Radiology|May 24, 2024
Assessing the effectiveness of MRI, <sup>18</sup>F-fluciclovine PET, SUV<sub>max</sub>, and PSA in detecting local recurrence of prostate cancer after prostatectomyMayur K Virarkar, Stephen K Gruschkus, Gregory C Ravizzini, et al.
American Journal of Nuclear Medicine and Molecular Imaging|June 3, 2021
Diagnostic performance of <sup>18</sup>F-fluciclovine PET/CT in prostate cancer patients with rising PSA level ≤ 0.5 ng/ml after multiple treatment failuresAjalaya Teyateeti, Achiraya Teyateeti, Gregory C Ravizzini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2010
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancerGustavo S P Meirelles, Heiko Schöder, Gregory C Ravizzini, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|October 27, 2019
Fully automated preparation of <sup>68</sup>Ga-PSMA-11 at curie level quantity using cyclotron-produced <sup>68</sup>Ga for clinical applicationsMai Lin, Vincenzo Paolillo, Robert T Ta, et al.
Prostate Cancer and Prostatic Diseases|December 13, 2017
The use of PET/CT in prostate cancerRoger Li, Gregory C Ravizzini, Michael A Gorin, et al.
The Journal of Urology|June 23, 2023
Diagnostic Performance and Safety of <sup>18</sup>F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). ReplyAshesh B Jani, Gregory C Ravizzini, Benjamin A Gartrell, et al.
Radiology|March 24, 2010
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlationBaris Turkbey, Peter A Pinto, Haresh Mani, et al.
The Journal of Urology|July 7, 2023
Reply by AuthorsAshesh B Jani, Gregory C Ravizzini, Benjamin A Gartrell, et al.
The Journal of Urology|May 1, 2023
Diagnostic Performance and Safety of <sup>18</sup>F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)Ashesh B Jani, Gregory C Ravizzini, Benjamin A Gartrell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 13, 2024
Interreader and Intrareader Reproducibility of <sup>18</sup>F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter StudiesPhillip H Kuo, Giuseppe Esposito, Gary A Ulaner, et al.
Pageof 3